Emergent BioSolutions (FRA:ER4) Net Change in Cash : €-9.1 Mil (TTM As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Emergent BioSolutions's Net Change in Cash for the three months ended in Dec. 2024 was €-48.5 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €-9.1 Mil.

Emergent BioSolutions Net Change in Cash Historical Data

The historical data trend for Emergent BioSolutions's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Net Change in Cash Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

372.78

-40.00

62.59

-486.84

-5.82

Emergent BioSolutions Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															21.92	-30.08	-7.43	76.95	-48.51

Emergent BioSolutions Net Change in Cash Calculation

Emergent BioSolutions's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	56.059	+	119.566	+	-181.45	+	0
	=	-5.8

Emergent BioSolutions's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -76.305 + 27.313 + 0.478 + 0

= -48.5

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Emergent BioSolutions's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (FRA:ER4) » Definitions » Net Change in Cash

Comparable Companies

AQST TKNO LFCR RGC ANIK ESPR DERM ETON BIOA ELTP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA

Traded in Other Exchanges

EBS:USA 0IGA:UK ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines